


PHARMACEUTICAL 2023



Reneo Pharmaceuticals Inc. Rank 90 of 446





PHARMACEUTICAL 2023



Reneo Pharmaceuticals Inc. Rank 90 of 446



The relative strengths and weaknesses of Reneo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Reneo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Reneo Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 163% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	106,353
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,124
Liabilities, Non-Current	1,059
Other Assets	1,376
Other Compr. Net Income	-77
Other Expenses	0
Other Liabilities	29
Other Net Income	1,893
Other Revenues	0
Property and Equipment	453
Research and Development	37,705
Selling, General and Administrative Expense	16,143

Output Variable	Value in 1000 USD
Assets	108,182
Liabilities	8,212
Expenses	53,848
Revenues	0
Stockholders Equity	99,970
Net Income	-51,955
Comprehensive Net Income	-51,994
Economic Capital Ratio	206%

